Pramlintide Pregnancy and Breastfeeding Warnings
Brand names: Symlin, Symlin Pen, SymlinPen 120, SymlinPen 60
Medically reviewed by Drugs.com. Last updated on Dec 9, 2024.
Pramlintide Pregnancy Warnings
This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
US FDA pregnancy category: C
Animal studies have shown increases in congenital abnormalities (neural tube defect, cleft palate, exencephaly). There are no controlled data in human pregnancy. Additionally, studies have shown low potential to cross the maternal/fetal placental barrier.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Pramlintide Breastfeeding Warnings
This drug should be used only if the potential benefit outweighs the potential risk to the infant.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- (2005) "Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc
References for breastfeeding information
- (2005) "Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.